The total return over the past 12 months is +49.71% vs. +16.94% for the S&P 500. So far it's up -27.95% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | +49.71% | +66.77% | (7.68%) | +12.41% | N/A | N/A |
| Total Return CAGR | +49.71% | +66.77% | (7.68%) | +12.41% | N/A | N/A |
| Revenue CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Relmada Therapeutics, Inc. (RLMD)
| Year | Start price | End price | RLMD Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $4.83 | $3.48 | (27.95%) | +14.51% | (42.46%) |
| 2025 | $0.52 | $4.83 | +828.85% | +17.72% | +811.13% |
| 2024 | $1.03 | $0.52 | (49.51%) | +24.89% | (74.40%) |
| 2023 | $0.87 | $1.03 | +18.05% | +26.19% | (8.14%) |
| 2022 | $4.51 | $0.87 | (80.65%) | (18.17%) | (62.48%) |
| 2021 | $6.41 | $4.51 | (29.64%) | +28.74% | (58.38%) |
| 2020 | $7.80 | $6.41 | (17.82%) | +18.37% | (36.19%) |
| 2019 | $0.92 | $7.80 | +747.83% | +31.22% | +716.61% |
| 2018 | $0.60 | $0.92 | +53.33% | (4.56%) | +57.89% |
| 2017 | $0.87 | $0.60 | (31.19%) | +21.70% | (52.89%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
